ALBI score predicts mortality risk in patients with non-ST-segment elevation myocardial infarction

This retrospective cohort study included 982 patients diagnosed with non-ST-segment elevation myocardial infarction (NSTEMI). The primary exposure was the albumin-bilirubin (ALBI) score, assessed to determine its relationship with clinical outcomes following hospitalization. The study did not report a specific comparator group or intervention details beyond the exposure assessment.

The main result indicated that the ALBI index was associated with a hazard ratio of 5.07 for mortality after hospital discharge. The 95% confidence interval for this estimate ranged from 3.13 to 8.20. In terms of absolute numbers, 62 deaths occurred out of the 982 participants included in the analysis.

Safety data, tolerability, and adverse events were not reported in the provided evidence. The study design is a retrospective cohort study, which limits the ability to establish causality. Key limitations regarding follow-up duration and potential confounding factors were not reported. Consequently, the clinical relevance of the ALBI score for routine mortality prediction in NSTEMI patients requires cautious interpretation.